Prioritising returns to shareholders. Not a surprise given the problems in Indore following FDA warning letter. Results were OK but creditors will not be pleased with the emphasis on shareholder returns.
• Total Revenue $3.254bn -11% reported but -2% when adjusted for divestiture of OTC business to Cooper
• Adj EBITDA $923m (-12%) ; FCF $535m (-13%)
• Brands increased Adj Sales by +3% to $2.1bn
• Generics fell 11% to $1.1bn impacted by Indore outage
• Reaffirms commitment to returning capital to shareholders. YTD has paid $450m to shareholders in dividends and share buybacks
• Guidance more or less unchanged. Total revenue $13,75bn; Adj EBITDA $4.04bn (down 10m); FCF $2bn
Find more articles and bullets on these widgets:
2.625% Jul-28 EU-bond (EU000A4D5QM6)
2.50% Oct-52 EU-bond (EU000A3K4DT4)
For both:
From market source
SX7E (17th Apr) 155/150ps vs 171c, bought the ps for 0.25 in ~7.2k.